# Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab

> **NCT00139841** · PHASE3 · COMPLETED · sponsor: **Cephalon** · enrollment: 103 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Bendamustine HCl

## Key facts

- **NCT ID:** NCT00139841
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-07
- **Final completion:** 2009-10
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00139841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00139841, "Safety and Efficacy of Treanda™ (Bendamustine HCl) in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Who Are Refractory to Rituximab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00139841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*